927679-54-7 Usage
Uses
Used in Pharmaceutical Industry:
(1R,5S,6R)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-carboxylic acid is used as a potential pharmaceutical agent for its unique structure and functional groups, which may allow it to interact with biological receptors or enzymes, contributing to the development of new drugs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (1R,5S,6R)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-carboxylic acid is utilized for its potential to be further modified or used as a building block in the synthesis of new medicinal compounds, given its specific molecular features.
Used in Organic Synthesis:
(1R,5S,6R)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-carboxylic acid is employed as a protecting group in organic synthesis, where the tert-butoxycarbonyl group can be selectively removed under mild conditions, facilitating the synthesis of more complex organic molecules.
Further research and testing are required to fully explore the properties and potential applications of this compound across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 927679-54-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,7,6,7 and 9 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 927679-54:
(8*9)+(7*2)+(6*7)+(5*6)+(4*7)+(3*9)+(2*5)+(1*4)=227
227 % 10 = 7
So 927679-54-7 is a valid CAS Registry Number.
InChI:InChI=1/C11H17NO4/c1-11(2,3)16-10(15)12-4-6-7(5-12)8(6)9(13)14/h6-8H,4-5H2,1-3H3,(H,13,14)/t6-,7+,8+
927679-54-7Relevant articles and documents
ALKYNYL QUINAZOLINE COMPOUNDS
-
Paragraph 1159, (2021/02/19)
The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.
NOVEL 6-PYRAZOLYLAMIDO-3-SUBSTITUTED AZABICYCLO[3.1.0]HEXANE COMPOUNDS AS CALCIUM CHANNEL INHIBITORS
-
, (2014/12/09)
The present invention relates to a 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane derivatives useful as calcium channel blockers, pharmaceutically acceptable salts thereof and medical use of the calcium channel inhibiting effect of the compounds for treatment of diseases.
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead
Jones, Carrie K.,Sheffler, Douglas J.,Williams, Richard,Jadhav, Sataya B.,Felts, Andrew S.,Morrison, Ryan D.,Niswender, Colleen M.,Daniels, J. Scott,Conn, P. Jeffrey,Lindsley, Craig W.
, p. 1067 - 1070 (2014/03/21)
This Letter describes the development and SAR of a novel series of GlyT1 inhibitors derived from a scaffold hopping approach that provided a robust intellectual property position, in lieu of a traditional, expensive HTS campaign. Members within this new [3.1.0]-based series displayed excellent GlyT1 potency, selectivity, free fraction, CNS penetration and efficacy in a preclinical model of schizophrenia (prepulse inhibition).
